Janus kinase inhibitors for alopecia areata.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37591562.
- Also identified by DOI 10.1016/j.jaad.2023.05.049.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Janus kinase (JAK) inhibitors have ushered in a new era in alopecia areata (AA). Historically, moderate-to-severe AA was refractory to treatment. JAK inhibitors have changed that; now, treatment of moderate-to-severe AA is possible. Here, we briefly review the history of and rationale for JAK inhibitor treatment of AA, phase 3 clinical trial data, and considerations regarding differences among JAK inhibitors, safety, and patient selection.
Medical subject headings
- Alopecia Areata
- Janus Kinase Inhibitors